Copyright
©The Author(s) 2016.
World J Gastroenterol. Sep 28, 2016; 22(36): 8211-8218
Published online Sep 28, 2016. doi: 10.3748/wjg.v22.i36.8211
Published online Sep 28, 2016. doi: 10.3748/wjg.v22.i36.8211
Figure 4 Outcomes of follow-up patient subset.
Clinical outcomes in the follow-up subgroup according to FC result. FC: Fecal calprotectin; IBD: Inflammatory bowel disease.
- Citation: Rosenfeld G, Greenup AJ, Round A, Takach O, Halparin L, Saadeddin A, Ho JK, Lee T, Enns R, Bressler B. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World J Gastroenterol 2016; 22(36): 8211-8218
- URL: https://www.wjgnet.com/1007-9327/full/v22/i36/8211.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i36.8211